Rigel has an exclusive license and supply agreement with Knight to commercialize TAVALISSE (fostamatinib disodium hexahydrate) in all potential indications in Latin America.
Knight has submitted marketing authorization applications for TAVALISSE in Brazil, Colombia and Mexico.
In December 2024, Knight announced Mexico's Comisión Federal para la Protección contra Riesgos Sanitarios approved TAVALISSE for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Rigel received an upfront cash payment, and is eligible for additional regulatory and commercial milestone payments, and royalty payments based on tiered net sales of TAVALISSE in the territory.